Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
Carrie L. Kitko(Vanderbilt University Medical Center), Stephanie J. Lee(Fred Hutch Cancer Center)
Cited by 94
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
|Journal of Clinical Oncology|2006|2k
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435